{"id":"high-dose-meropenem","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Seizures (particularly with meningitis or renal impairment)"},{"rate":null,"effect":"Phlebitis at injection site"}]},"_chembl":{"chemblId":"CHEMBL127","moleculeType":"Small molecule","molecularWeight":"383.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Meropenem is a carbapenem antibiotic that penetrates bacterial cell walls and irreversibly binds to penicillin-binding proteins, inhibiting cross-linking of peptidoglycan and leading to cell wall disruption and bacterial death. High-dose formulations are used to achieve elevated concentrations in tissues and cerebrospinal fluid, particularly for serious infections caused by resistant gram-negative organisms or in meningitis.","oneSentence":"High-dose meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:41.690Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Serious bacterial infections caused by susceptible organisms"},{"name":"Bacterial meningitis"},{"name":"Hospital-acquired infections with resistant gram-negative bacteria"}]},"trialDetails":[{"nctId":"NCT07326540","phase":"PHASE3","title":"Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus Complex","status":"NOT_YET_RECRUITING","sponsor":"BioVersys SAS","startDate":"2026-03-20","conditions":"Hospital Acquired Bacterial Pneumonia (HABP), Ventilator Associated Bacterial Pneumonia (VABP), Colistin Resistanrt ABC","enrollment":248},{"nctId":"NCT07236944","phase":"PHASE4","title":"Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care","status":"RECRUITING","sponsor":"Uppsala University","startDate":"2025-12","conditions":"Febrile Urinary Tract Infection","enrollment":560},{"nctId":"NCT06184659","phase":"PHASE4","title":"Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis","status":"RECRUITING","sponsor":"Scandinavian Critical Care Trials Group","startDate":"2025-06-26","conditions":"Sepsis, Septic Shock","enrollment":5800},{"nctId":"NCT07004049","phase":"PHASE4","title":"Optimising TREATment for Severe Gram-Negative Bacterial Infections","status":"RECRUITING","sponsor":"National University of Singapore","startDate":"2025-04-21","conditions":"Bloodstream Infection, Ventilator Associated Bacterial Pneumonia, Hospital Acquired Bacterial Pneumonia","enrollment":600},{"nctId":"NCT06818565","phase":"NA","title":"Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-02-10","conditions":"Acute-On-Chronic Liver Failure","enrollment":150},{"nctId":"NCT03507751","phase":"","title":"Pharmacokinetics of Meropenem During High-dose CRRT","status":"COMPLETED","sponsor":"Medical University of Lublin","startDate":"2018-04-02","conditions":"Infection, Renal Failure","enrollment":19},{"nctId":"NCT03034174","phase":"","title":"Pharmacokinetics of High-dose Tigecycline in Critically Ill Patients","status":"COMPLETED","sponsor":"Medical University of Lublin","startDate":"2017-01-15","conditions":"Septic Shock, Antibiotic Resistant Infection, Critical Illness","enrollment":37},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT04876430","phase":"PHASE2, PHASE3","title":"Best Available Therapy With or Without Meropenem for Bloodstream Infections by Enterobacterales With High Level of Resistance to Carbapenems","status":"TERMINATED","sponsor":"Hospital de Clinicas de Porto Alegre","startDate":"2021-05-04","conditions":"Carbapenem-Resistant Enterobacteriaceae Infection, Bloodstream Infection","enrollment":13},{"nctId":"NCT03344627","phase":"NA","title":"Clinical Outcome Study of High-dose Meropenem in Sepsis and Septic Shock Patients","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-11-27","conditions":"Sepsis, Septic Shock, Critical Illness","enrollment":76}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":56,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"High-dose meropenem","genericName":"High-dose meropenem","companyName":"National University of Singapore","companyId":"national-university-of-singapore","modality":"Small molecule","firstApprovalDate":"","aiSummary":"High-dose meropenem is a broad-spectrum beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Serious bacterial infections caused by susceptible organisms, Bacterial meningitis, Hospital-acquired infections with resistant gram-negative bacteria.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}